After TikTok, China Biotech Stands Under Congressional Scrutiny
Monday, 9 September 2024, 13:10
US Congressional Action on China Biotech
After TikTok, the US Congress is turning its attention to Chinese biotech firms. As lawmakers strive to take decisive steps, both domestic and international markets may be affected. The decision could reshape the landscape for Chinese biotech and its partnerships in the US.
Key Legislative Moves
- Blacklisting firms that engage in activities seen as threatening.
- Addressing perceived risks in national security.
- Pushing back against lobbying efforts to shield companies.
The potential fallout of these actions could lead to strained relations and altered investment strategies within the biotech sector.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.